The following individuals have expressed opinions on iCo Therapeutics and may be contacted directly for copies of their reports. Please view our Cautionary Notes regarding this list.
| Publication | Name | Contact |
| Emerging drug developer in attractive ocular disease space | Douglas W. Loe, Ph.D, MBA, Versant Partners | mluckevich@lomltd.com (416) 964-4430 |
| The Next Wave (Dundee Biotech) | David Martin, PhD, MBA, Dundee Securities | Dundee has since been acquired by Scotiabank. |